Terminal
Terminal/Skill
Explains CMS-HCC risk adjustment methods, including V24 and V28 model versions, ICD-10 to HCC mapping and finding coding gaps.
By Amazon Web Services
Works with
npx skills add awslabs/hcls-agent-skills --skill risk-adjustment-strategyGuide the agent through CMS-HCC risk adjustment methodology, model version differences, hierarchy resolution, coding gap identification, and audit-defensible documentation requirements. This skill encodes regulatory and actuarial knowledge for risk adjustment programs, primarily Medicare Advantage (Part C).
CMS pays Medicare Advantage (MA) plans a capitated amount per member per month. The payment is adjusted based on the member's health status, measured by diagnoses submitted on claims. Sicker members generate higher payments (higher RAF scores). The CMS-HCC model translates ICD-10-CM diagnosis codes into Hierarchical Condition Categories (HCCs) and calculates a Risk Adjustment Factor (RAF) score.
RAF = demographic_coefficient
+ SUM(hcc_coefficients for all active HCCs after hierarchy resolution)
+ SUM(disease_interaction_terms)
+ coding_intensity_adjustment (negative, applied by CMS)
| Attribute | V24 (Legacy) | V28 (Current) |
|---|---|---|
| Number of HCCs | 86 | 115 |
| Payment year | Through 2023 (blended 2024–2025) | 2026+ (full weight) |
| Key additions | — | Substance use disorders, social determinants proxies, expanded mental health |
| Key removals | — | Some lower-severity HCCs consolidated |
| Coefficient source | 2015–2016 FFS data | 2017–2018 FFS data |
| Coding intensity adj. | -5.90% (2024) | Built into coefficients |
| Payment Year | V24 Weight | V28 Weight |
|---|---|---|
| 2024 | 67% | 33% |
| 2025 | 33% | 67% |
| 2026+ | 0% | 100% |
Implication: During the transition, BOTH models must be run and blended. A diagnosis that maps to an HCC in V24 but not V28 (or vice versa) has partial payment impact.
ICD-10-CM code
→ CMS crosswalk → Condition Category (CC)
→ Hierarchy resolution → HCC (only highest-severity CC in each hierarchy retained)
→ Coefficient lookup → RAF contribution
| CC | Description | Hierarchy Position | V24 Coefficient (Community, Non-Dual, Aged) |
|---|---|---|---|
| 17 | Diabetes with Acute Complications | Highest | 0.368 |
| 18 | Diabetes with Chronic Complications | ↓ | 0.368 |
| 19 | Diabetes without Complication | Lowest | 0.118 |
Rule: If a member has both CC 17 and CC 19, only CC 17 (HCC 17) is retained. CC 19 is "hierarchied off."
| Hierarchy Group | CCs (V24, highest → lowest) | Clinical Area |
|---|---|---|
| Diabetes | 17 → 18 → 19 | Endocrine |
| Heart Failure | 85 → 86 → 87 | Cardiovascular |
| COPD | 111 → 112 | Pulmonary |
| Renal | 136 → 137 → 138 | Nephrology |
| Cancer | 8 → 9 → 10 → 11 → 12 | Oncology |
| Vascular | 107 → 108 | Cardiovascular |
CMS recognizes that certain combinations of HCCs have a greater-than-additive cost impact. Interaction terms add additional RAF points when specific HCC pairs (or groups) co-occur.
| Interaction | HCCs Required | Additional Coefficient |
|---|---|---|
| Diabetes + CHF | HCC 17/18 + HCC 85/86 | +0.154 |
| CHF + COPD | HCC 85/86 + HCC 111/112 | +0.175 |
| CHF + Renal | HCC 85/86 + HCC 136/137/138 | +0.154 |
| Diabetes + CHF + COPD | HCC 17/18 + HCC 85/86 + HCC 111/112 | +0.047 (additional) |
| Cancer + Immune | HCC 8/9/10/11/12 + HCC 47 | +0.190 |
Rule: Interaction terms are ONLY applied if the component HCCs survive hierarchy resolution. If a higher-severity CC in the same hierarchy replaces a component, re-check whether the interaction still qualifies.
A coding gap exists when clinical evidence suggests a condition is present, but no qualifying ICD-10 code has been submitted on a face-to-face claim in the current payment year.
| Medication (Rx) | Suspected Condition | Target HCC (V24) |
|---|---|---|
| Metformin, glipizide, insulin | Diabetes mellitus | HCC 19 (or 17/18 with complications) |
| Statins (atorvastatin, rosuvastatin) | Hyperlipidemia | No HCC (but may indicate vascular disease) |
| Lisinopril, losartan | Hypertension | No HCC (but may indicate CHF, renal disease) |
| Furosemide, spironolactone | Heart failure | HCC 85/86/87 |
| Albuterol, fluticasone/salmeterol | COPD or asthma | HCC 111/112 |
| Donepezil, memantine | Dementia | HCC 51/52 |
| Warfarin, apixaban | Atrial fibrillation or DVT/PE | HCC 96 or 107/108 |
| Methotrexate, adalimumab | Rheumatoid arthritis | HCC 40 |
Rule: Rx proxies identify SUSPECTED gaps. They are NOT sufficient for coding — a provider must document and code the condition on a qualifying encounter.
| Lab Result | Suspected Condition | Target HCC |
|---|---|---|
| HbA1c ≥ 6.5% | Diabetes mellitus | HCC 19+ |
| eGFR < 60 mL/min | Chronic kidney disease | HCC 136/137/138 |
| BNP > 100 pg/mL | Heart failure | HCC 85/86/87 |
| TSH > 10 mIU/L | Hypothyroidism | No HCC |
| BMI ≥ 40 | Morbid obesity | HCC 22 |
Conditions documented in the prior year but not yet recaptured in the current year.
Decision tree for gap prioritization:
Is the condition chronic (expected to persist year-over-year)?
├─ YES
│ ├─ Was it documented in the prior year?
│ │ ├─ YES → High-priority recapture gap
│ │ └─ NO → New gap identified by Rx/lab proxy
│ └─ Does it map to an HCC?
│ ├─ YES → Revenue-impacting gap → prioritize
│ └─ NO → Clinical gap only → lower priority for risk adjustment
└─ NO (acute condition)
└─ Do NOT assume recapture; only code if currently active
CMS conducts Risk Adjustment Data Validation (RADV) audits to verify that submitted diagnoses are supported by medical record documentation.
Does the medical record contain:
├─ A face-to-face encounter note? → If NO, diagnosis is NOT audit-defensible
├─ Provider signature/authentication? → If NO, not defensible
├─ The condition listed in the assessment/plan? → If NO, not defensible
├─ Evidence of evaluation or management of the condition?
│ (e.g., medication review, test ordering, counseling)
│ → If NO, not defensible (listing alone is insufficient)
└─ Specificity matching the ICD-10 code?
(e.g., "diabetes with nephropathy" for E11.21, not just "diabetes")
→ If NO, code must be downgraded to the supported specificity level
| Failure | Example | Risk |
|---|---|---|
| Problem list only | Diabetes on problem list but not addressed in note | HCC deleted on audit |
| Cloned notes | Identical assessment across multiple visits | All HCCs at risk |
| Unspecified codes | E11.9 (diabetes unspecified) when complications exist | Missed higher HCC |
| Missing laterality | I63.511 vs I63.512 (stroke, right vs left) | Code rejected |
| Resolved conditions | "History of cancer" coded as active cancer | HCC deleted + penalty |
| Missing provider type | Diagnosis from lab-only encounter | Does not qualify |
| Priority | Criteria | Action |
|---|---|---|
| Critical | HCC coefficient > 0.3 AND chronic condition | Schedule dedicated visit or ensure addressed at next visit |
| High | HCC coefficient 0.15–0.3 AND chronic | Address at next scheduled visit |
| Medium | HCC coefficient < 0.15 AND chronic | Address opportunistically |
| Low | Acute condition from prior year | Do NOT recapture unless condition is still active |
| Quarter | Strategy |
|---|---|
| Q1 (Jan–Mar) | Begin recapture for highest-value HCCs; schedule annual wellness visits |
| Q2 (Apr–Jun) | Mid-year gap report; target members with no visits yet |
| Q3 (Jul–Sep) | Escalate outreach for members with open high-value gaps |
| Q4 (Oct–Dec) | Final sweep; focus on members with scheduled visits remaining |
Which model version should I optimize for?
├─ Payment year 2024?
│ └─ Run BOTH V24 and V28. Weight: 67% V24 + 33% V28.
│ Focus on V24 HCCs (higher weight) but do not ignore V28-only HCCs.
├─ Payment year 2025?
│ └─ Run BOTH. Weight: 33% V24 + 67% V28.
│ Shift focus to V28 HCCs.
└─ Payment year 2026+?
└─ V28 only.
| Change Type | Example | Impact |
|---|---|---|
| Removed in V28 | Some lower-severity CCs consolidated | Lost revenue if only V28 applies |
| New in V28 | Substance use disorders, expanded mental health | New revenue opportunity |
| Coefficient changed | Diabetes coefficients recalibrated | May increase or decrease RAF |
| Hierarchy restructured | Some hierarchies split or merged | Different CC may survive hierarchy |
Rule: During the transition, a diagnosis that maps to an HCC in V24 but NOT V28 still has partial value (67% in 2024, 33% in 2025). Do not ignore these diagnoses.
Wrong: Coding diagnoses directly from Rx claims without a face-to-face encounter Right: Use Rx data to identify suspected gaps, then document the condition via a qualifying face-to-face encounter Why: Rx claims are proxies, not diagnosis sources — CMS requires face-to-face documentation for risk adjustment
Wrong: Recapturing conditions that have resolved (e.g., coding "history of cancer" as active cancer) Right: Only code conditions that are currently active and being evaluated, monitored, or treated Why: "History of" is not an active diagnosis; submitting resolved conditions as active is audit-indefensible and may constitute fraud
Wrong: Calculating RAF scores without applying hierarchy resolution Right: Always resolve hierarchies (retain only the highest-severity CC in each group) before summing coefficients Why: Counting superseded CCs overstates the RAF score and produces incorrect revenue projections
Wrong: Optimizing coding strategy for V24 only during the 2025 payment year Right: Run both V24 and V28 models with appropriate blend weights (33% V24 / 67% V28 in 2025) Why: V28 carries 67% weight in 2025; ignoring it means missing the majority of payment impact
Wrong: Submitting diagnoses from lab-only or radiology-only encounters Right: Ensure every submitted diagnosis comes from a face-to-face encounter with a qualifying provider type (MD, DO, NP, PA) Why: Lab-only encounters do not qualify for risk adjustment under CMS rules — these diagnoses will be deleted on RADV audit
Wrong: Cloning documentation across multiple visits with identical assessment text Right: Ensure each encounter note reflects the specific visit with unique clinical details and current status Why: Cloned notes put all associated HCCs at risk during audit — CMS may delete every HCC from cloned documentation
Wrong: Submitting unspecified ICD-10 codes when clinical documentation supports higher specificity Right: Code to the highest specificity level supported by the documentation (e.g., E11.21 instead of E11.9) Why: Unspecified codes may map to a lower-value HCC or no HCC at all, leaving revenue on the table
Every risk adjustment analysis MUST report:
| Term | Definition |
|---|---|
| CC | Condition Category — intermediate grouping of ICD-10 codes |
| HCC | Hierarchical Condition Category — CC that survives hierarchy resolution |
| RAF | Risk Adjustment Factor — numeric score representing expected cost |
| RADV | Risk Adjustment Data Validation — CMS audit program |
| MA | Medicare Advantage — Part C managed care plans |
| FFS | Fee-for-Service — traditional Medicare payment model |
| ESRD | End-Stage Renal Disease — separate CMS-HCC model |
| AWV | Annual Wellness Visit — key encounter for HCC recapture |
| NPI | National Provider Identifier |
| PY | Payment Year — the calendar year for which RAF scores are calculated |